Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tie-up with Kowa Could Evolve into Full Integration: Mr Tamura of Nikken Chemicals
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 3, 2004
- 6 New Drugs Including Visdyne Added to the NHI Price List
May 3, 2004
- PRESS SEMINAR
May 3, 2004
- REGULATORY NEWS IN BRIEF
May 3, 2004
- BULLETIN
May 3, 2004
- JRCS to Build Large-scale Clinical Trial Network
May 3, 2004
- OTC NEWS IN BRIEF
May 3, 2004
- Terumo Aims for 10th Consecutive Year of Growth in FY2004
May 3, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 3, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 3, 2004
- WORLD NEWS IN BRIEF
May 3, 2004
- Meet the Leaders (32)
May 3, 2004
- AstraZeneca Committed to Maintaining Top Position in Oncology
May 3, 2004
- Tokushukai Group to Establish Large-scale Clinical Trial Network
May 3, 2004
- Sankyo Aims for \15 Bil. Sales in China by 2010
May 3, 2004
- JOS Prepares Photodynamic Therapy GL
May 3, 2004
- FPMAJ Petitions for 8-Year Data Protection Period for New Drugs
May 3, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 3, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…